This bill would strengthen the Food and Drug Administration’s (FDA) authority to seize, detain, refuse, or destroy imports of drugs that are under development and considered controlled substances. Individuals or companies found to have violated this bill’s provisions would face fines and debarment by the FDA — meaning they’d be prohibited from providing services to a person or entity that has an approved or pending drug application.
- Not enactedThe President has not signed this bill
- The senate has not voted
Committee on Health, Education, Labor, and Pensions
- senate Committees
- The house Passed June 13th, 2018Passed by Voice Vote
Committee on Energy and CommerceHealthIntroducedMay 10th, 2018
- house Committees